Sixth, the HR and 95% CI of developing hypertension in SGLT2i users was 0.93 (0.86–1.01) compared to that in DPP4 inhibitor users after excluding individuals who had any antidiabetic medications at the index date (Supplementary Table 6). Here, DPP4 is linked to hypertensive disorder.